We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DxS and Amgen Enter into Collaboration to Provide a K-RAS Companion Diagnostic for Vectibix® in the United States

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

DxS has signed an agreement with Amgen Inc. to provide a K-RAS companion diagnostic for Vectibix® (panitumumab) in the United States.

Pursuant to the terms of the agreement, DxS and Amgen shall work together to further facilitate the use of Vectibix® in metastatic colorectal cancer patients with wild-type K-RAS status in the United States, with the intent that DxS’ TheraScreen: K-RAS Mutation Kit will become a companion diagnostic for use with Vectibix® if approved by the FDA.

This agreement between Amgen and DxS follows a collaboration entered into by the parties last year with respect to the TheraScreen: K-RAS Mutation Kit in Europe.

Dr Stephen Little, CEO of DxS said: “We are very pleased to be working with Amgen and building on our relationship. We believe that this agreement is a further endorsement of the capabilities of our K-RAS diagnostic test. We look forward to working with Amgen and the FDA to ensure that colorectal cancer patients in the USA have access to a K-RAS diagnostic test kit.”

Financial terms of the agreement are not disclosed.